Bio Data Studio @BioDataStudio

Richter’s shares soar following the U.S. approval of its drug, signaling strong market confidence in the Hungarian pharma giant's future prospects. hungarytoday.hu/pharma-giant-r…

Ionis Pharmaceuticals' stock has surged 85% recently, boosted by the approval of its ALS drug. The stock rose 5% in the past week, raising questions about its ongoing attractiveness for investors. simplywall.st/stocks/us/phar…

Aurinia's stock declines after an FDA official criticizes Lupkynis, the company's key lupus treatment approved in 2021, on LinkedIn. sherwood.news/markets/pharma…

Ionis Pharmaceuticals has seen an 85% rally recently, driven by the approval of its ALS drug. The stock is currently up 5%, raising questions about its future attractiveness for investors. simplywall.st/stocks/us/phar…

Crinetics Pharmaceuticals receives FDA approval for its acromegaly drug, a significant milestone after testing 807 molecules. The San Diego biotech now faces competition from Novartis and Ipsen in the marketplace. statnews.com/2025/09/25/new…

Crinetics Pharmaceuticals has received FDA approval for a new acromegaly treatment, after testing 807 molecules. The San Diego biotech faces competition from Novartis and Ipsen in the market. statnews.com/2025/09/25/new…

Crinetics Pharmaceuticals has received FDA approval for its daily pill to treat acromegaly, following extensive testing of 807 molecules. The company now faces competition from Novartis and Ipsen in the market. statnews.com/2025/09/25/new…

ARS Pharmaceuticals has requested the FDA to postpone the approval of Aquestive's epinephrine film for allergic reactions, raising concerns over safety, dosing, and cardiovascular issues. benzinga.com/news/health-ca…

Ionis Pharmaceuticals reports positive results from its pivotal study for a drug targeting a rare genetic disease with no approved treatments, showing improved walking speed in patients with muscle control issues. medcitynews.com/2025/09/ionis-…

Ionis Pharma reports that its drug for a rare genetic disease achieved key goals in pivotal studies, with patients showing improved walking speed despite previously lacking approved treatments. medcitynews.com/2025/09/ionis-…

The FDA's accelerated drug approval pathway offers quicker review times but could expose pharmaceutical companies to increased litigation risks amid shifting priorities under the Trump administration. biopharmadive.com/news/fda-accel…

FDA changes set for 2025 could complicate the approval process for vaccines and complex biologics, as the agency faces staffing challenges. cen.acs.org/pharmaceutical…

The FDA's accelerated drug approval pathway could bring swift access to medicines but may also expose pharmaceutical companies to increased litigation risks amid shifting regulatory priorities from the Trump administration. biopharmadive.com/news/fda-accel…

KalVista Pharmaceuticals' Ekterly has been approved as the first and only oral on-demand treatment for hereditary angioedema in the EU and Switzerland, contributing to a projected stock rally to $22 within the year. stocktwits.com/news-articles/…

Tonix Pharmaceuticals got FDA approval for Tonmya™ (cyclobenzaprine HCl sublingual tablets), the first new fibromyalgia therapy in 15+ years, targeting chronic pain linked to the condition. finance.yahoo.com/news/tonix-pha…

FDA changes set for 2025 could impact drug approvals, with vaccines and complex biologics facing greater challenges due to the agency's staffing issues. cen.acs.org/pharmaceutical…

FDA chief Martin Makary attributes longstanding regulatory failures to misleading pharma advertisements. The agency plans to proactively monitor companies for breaches of advertising laws. pharmaceutical-technology.com/news/fda-chief…

FDA chief Martin Makary attributes long-standing regulatory failures to misleading pharma advertisements. The agency will now proactively monitor companies for compliance with advertising laws. pharmaceutical-technology.com/news/fda-chief…

FDA chief Martin Makary attributes decades of regulatory failures to misleading pharma advertisements. The agency plans to implement proactive monitoring of pharmaceutical companies to ensure compliance with advertising laws. pharmaceutical-technology.com/news/fda-chief…

Vanda Pharmaceuticals has requested a review from FDA Commissioner Martin Makary regarding the outgoing CDER Director's decision to uphold the approval of two generic versions of Hetlioz®. prnewswire.com/news-releases/…